企業プロフィール
Autolus Therapeutics plc 株価・ニュース・カタリスト
- ティッカー:
- AUTL
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United Kingdom
株価パフォーマンス
2.28 USD (+6.05%)
終値
最終更新: 2026年8月17日
466M USD
時価総額
株価変動の要因
As of Aug 17, 2026, AUTL closed up 6.05% at $2.28. No new same-company headline was identified in the current news window.
企業概要
Programmable T-Cell Therapy Company
Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.
AUCATZYL
AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Fast Off-Rate CAR Design
Obe-cel uses a fast off-rate CD19 binding domain intended to reduce excessive T-cell activation while preserving antitumor activity and persistence.
Integrated Manufacturing
Autolus controls manufacturing and product delivery, supporting launches in the United States and United Kingdom and providing infrastructure for additional cell-therapy programs.
Pipeline Expansion
The company is extending its T-cell platform into additional hematologic cancers and autoimmune disease while building on physician experience with obe-cel.
今後のカタリスト
- Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale. The market is watching whether the cell-therapy rollout can translate into durable adoption.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。